[go: up one dir, main page]

MX2019007010A - Compuestos y composiciones para el tratamiento del cancer. - Google Patents

Compuestos y composiciones para el tratamiento del cancer.

Info

Publication number
MX2019007010A
MX2019007010A MX2019007010A MX2019007010A MX2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A
Authority
MX
Mexico
Prior art keywords
formula
compounds
cancer
treatment
compositions
Prior art date
Application number
MX2019007010A
Other languages
English (en)
Other versions
MX381345B (es
Inventor
Zacharie Boulos
Gagnon Lyne
Grouix Brigitte
Laurin Pierre
Geerts Lillianne
Penney Christopher
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MX2019007010A publication Critical patent/MX2019007010A/es
Publication of MX381345B publication Critical patent/MX381345B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nuevos usos para compuestos de carboxilato de feniceltona y compuestos aromáticos sustituidos de Fórmula I, Fórmula 1.1, Fórmula 1.2, Fórmula 1A, Fórmula IB, Fórmula IC y Fórmula II y sus sales farmacéuticamente aceptables para el tratamiento del cáncer. Se describe el uso de una combinación de dos de estos compuestos y el uso de la combinación de uno de estos compuestos con un agente anticanceroso, tal como decarbazina, doxorrubicina, daunorrubicina, ciclofosfamida, busulfex, busulfán, vinblastina, vincristina, bleomicina, etopósido, topotecán, irinotecán, taxotere, taxol, 5-fluorouracilo, metotrexato, gemcitabina, cisplatino, carboplatino y clorambucilo.
MX2019007010A 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cancer. MX381345B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40706910P 2010-10-27 2010-10-27
PCT/CA2011/001179 WO2012097427A1 (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2019007010A true MX2019007010A (es) 2019-09-06
MX381345B MX381345B (es) 2025-03-12

Family

ID=46515034

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007010A MX381345B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cancer.
MX2013004832A MX365807B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013004832A MX365807B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cáncer.

Country Status (24)

Country Link
US (2) US9114118B2 (es)
EP (2) EP3443957B1 (es)
JP (2) JP6007186B2 (es)
KR (2) KR101821646B1 (es)
CN (2) CN103347509B (es)
AU (2) AU2011356583C1 (es)
BR (1) BR112013010507A2 (es)
CA (1) CA2816093C (es)
CL (1) CL2013001152A1 (es)
DK (2) DK2632452T3 (es)
EA (2) EA035494B1 (es)
ES (2) ES2703257T3 (es)
IL (2) IL225599A (es)
MX (2) MX381345B (es)
MY (2) MY184343A (es)
NZ (1) NZ610851A (es)
PH (2) PH12013500766B1 (es)
PL (2) PL3443957T3 (es)
PT (2) PT3443957T (es)
SG (2) SG10201807622WA (es)
TR (1) TR201819987T4 (es)
TW (2) TWI578983B (es)
WO (1) WO2012097427A1 (es)
ZA (1) ZA201303035B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500766B1 (en) * 2010-10-27 2017-09-29 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
RU2560702C1 (ru) * 2014-06-05 2015-08-20 Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") Фармацевтическая композиция для применения в онкологии
MY194308A (en) * 2014-10-10 2022-11-27 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis
EP3204000B1 (en) * 2014-10-10 2020-01-08 Liminal Biosciences Limited Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
RU2728782C2 (ru) 2014-11-12 2020-07-31 Лиминал Байосайенсиз Лимитед Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани
CN106267213A (zh) * 2015-05-27 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
CA3081839A1 (en) 2017-11-08 2019-05-16 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
AU2019393347A1 (en) * 2018-12-05 2021-07-22 Liminal Biosciences Limited Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
IL289919B2 (en) 2019-07-26 2025-10-01 Espervita Therapeutics Inc Long-chain functional mono- and dicarboxylic acids, useful for the prevention or treatment of diseases
CN116568291A (zh) * 2020-10-06 2023-08-08 殷格纽制药有限公司 取代的芳香族化合物及其药物组合物
AU2022209835A1 (en) 2021-01-25 2023-09-14 Espervita Therapeutics, Inc. Functionalized long-chain carboxylic acids, and their use for treatment of disease
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途
WO2024192529A1 (en) * 2023-03-22 2024-09-26 Uti Limited Partnership Hydroxyphenyl propanoate compounds for tumour immunotherapy, compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268907A3 (en) * 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 （4－炔基）－芳香酮酸类化合物、合成方法及应用
WO2004058787A2 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
WO2005010202A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
ES2376277T3 (es) 2006-09-01 2012-03-12 Piramal Life Sciences Limited Uso del �?cido cafeico y dervados como agentes anticancerosos.
CN105233294A (zh) * 2007-02-08 2016-01-13 爱密斯菲尔科技公司 苯烷基羧酸输送剂
WO2009055932A1 (en) * 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
RU2519215C2 (ru) * 2007-11-02 2014-06-10 Прометик Байосайенсиз Инк. Жирные кислоты и глицериды со средней длиной цепи в качестве нефропротективных средств
PT2231166E (pt) 2007-12-19 2013-06-17 Prometic Biosciences Inc Ácidos gordos com comprimento de cadeia média, sais e riglicéridos em combinação com gemcitabina para tratamento do cancro pancreático
ES2441800T3 (es) 2009-05-04 2014-02-06 Prometic Biosciences Inc. Sales de ácido 3-pentilfenilacético y usos farmacéuticos de las mismas
DK2427416T3 (en) 2009-05-04 2016-06-13 Prometic Pharma Smt Ltd Substituted aromatic compounds, and pharmaceutical uses thereof
PH12013500766B1 (en) * 2010-10-27 2017-09-29 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer

Also Published As

Publication number Publication date
PH12016502324B1 (en) 2023-10-11
CN103347509B (zh) 2016-06-08
KR20180011332A (ko) 2018-01-31
PL2632452T3 (pl) 2019-03-29
PT2632452T (pt) 2019-01-10
CN105997967A (zh) 2016-10-12
CN103347509A (zh) 2013-10-09
SG10201807622WA (en) 2018-10-30
KR101821646B1 (ko) 2018-01-25
EA201370103A1 (ru) 2013-12-30
EP3443957B1 (en) 2020-11-25
DK2632452T3 (en) 2019-01-21
SG189538A1 (en) 2013-06-28
EA035494B1 (ru) 2020-06-25
PH12016502324A1 (en) 2019-07-15
EP2632452A4 (en) 2014-05-07
TWI578983B (zh) 2017-04-21
AU2016201556B2 (en) 2017-09-14
BR112013010507A2 (pt) 2016-08-02
JP6007186B2 (ja) 2016-10-12
PH12013500766A1 (en) 2013-06-24
MX2013004832A (es) 2013-05-22
CL2013001152A1 (es) 2014-01-10
US9439882B2 (en) 2016-09-13
US9114118B2 (en) 2015-08-25
ES2837599T3 (es) 2021-06-30
ZA201303035B (en) 2014-06-25
IL225599A0 (en) 2013-06-27
AU2011356583A1 (en) 2013-05-09
AU2016201556A1 (en) 2016-04-14
CA2816093A1 (en) 2012-07-26
AU2011356583C1 (en) 2016-03-17
US20130217645A1 (en) 2013-08-22
EA030038B1 (ru) 2018-06-29
PL3443957T3 (pl) 2021-05-04
NZ610851A (en) 2015-05-29
JP6371344B2 (ja) 2018-08-08
MY184343A (en) 2021-04-01
KR20130132448A (ko) 2013-12-04
CN105997967B (zh) 2019-08-23
MX381345B (es) 2025-03-12
EP2632452B1 (en) 2018-09-26
CA2816093C (en) 2020-12-01
EP2632452A1 (en) 2013-09-04
TW201717928A (zh) 2017-06-01
US20150313856A1 (en) 2015-11-05
MX365807B (es) 2019-06-14
EP3443957A1 (en) 2019-02-20
TW201305097A (zh) 2013-02-01
JP2016188247A (ja) 2016-11-04
HK1189836A1 (zh) 2014-06-20
IL251083B (en) 2018-07-31
IL225599A (en) 2017-05-29
ES2703257T3 (es) 2019-03-07
PH12013500766B1 (en) 2017-09-29
JP2013544799A (ja) 2013-12-19
IL251083A0 (en) 2017-04-30
WO2012097427A1 (en) 2012-07-26
TR201819987T4 (tr) 2019-01-21
DK3443957T3 (da) 2020-12-21
TWI620563B (zh) 2018-04-11
AU2011356583B2 (en) 2015-12-24
PT3443957T (pt) 2020-12-18
EA201791585A1 (ru) 2018-05-31
MY162420A (en) 2017-06-15
KR101943280B1 (ko) 2019-01-28

Similar Documents

Publication Publication Date Title
MX2019007010A (es) Compuestos y composiciones para el tratamiento del cancer.
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
PH12017502141A1 (en) Compounds and their methods of use
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CR20180547A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2015003491A1 (es) Compuestos químicos.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
CO6480975A2 (es) Mimetico de smac
CO6592104A2 (es) Compuesto heterociclico
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX381967B (es) Compuestos de 2,3-dihidrobenzofuran-5-ilo como inhibidores de quinasas dyrk.
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen
TR201819805T4 (tr) Flavaglin türevleri̇.
CR20160016A (es) Pirazolpiridinas sustituidas